Apimeds Pharmaceuticals US (APUS) Return on Capital Employed (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Return on Capital Employed came in at 15.67% in Q4 2025, up 73.18% on a QoQ basis from 58.44% in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Return on Capital Employed (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 1 years of Return on Capital Employed data on file, last reported at 15.67% in Q4 2025.
- Quarterly Return on Capital Employed changed N/A year-over-year to 15.67% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15.67% (changed N/A YoY) and the FY2025 annual result came in at 16.69%, down 17474.0% from the prior year.
- Return on Capital Employed advanced to 15.67% in Q4 2025, from 58.44% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 83.71% in Q1 2025 to a low of 78.44% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.50 Mn | 7.50 Mn | - | -14.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.67% |
| Sep 30, 2025 | -58.44% |
| Jun 30, 2025 | -78.44% |
| Mar 31, 2025 | 83.71% |